Finance

Beta
Lists
Q2 2026 earnings • released • EPS beat +11.24% • Revenue beat +7.23%
See results
1SOBI:BIT
Swedish Orphan Biovitrum AB (publ)
€42.24
+0.76%
(+0.32) 1D
Jul 17, 2:30:46 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 1SOBI...
Mkt. cap
166.20B
Avg. vol.
17.00
Volume
0.00
52-wk high
€45.58
52-wk low
€23.74
No. of employees
2K
Mkt. cap
166.20B
Avg. vol.
17.00
Volume
0.00
52-wk high
€45.58
52-wk low
€23.74
No. of employees
2K
News stories
From sources across the web
Profile
Sobi - Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care. Headquartered in Stockholm, Sweden, with major hubs in Basel, Switzerland, and Waltham, USA. Sobi has a global presence in approximately 30 countries and provides medicines to patients in many more around world. In 2025 it had a revenue of SEK 28.2 billion and aorund 1,900 employees. Wikipedia
About Swedish Orphan Biovitrum AB (publ)
CEOGuido Oelkers
Employees2.12K
Founded1939
Headquarters-
SectorBiotechnology
Websitesobi.com
Last report
Jul 16, 2026
Fiscal period
Q2 2026
EPS / Est. (SEK)
SEK 3.96 / SEK 3.56
+11.24%beat
Revenue / Est. (SEK)
7.84B / 7.31B
+7.23%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in SEK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SEK
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
6.18B
7.78B
7.82B
7.18B
Cost of goods sold
1.39B
1.56B
1.51B
1.70B
Cost of revenue
1.39B
1.56B
1.51B
1.70B
Research and development expenses
783.00M
754.00M
879.00M
948.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.74B
2.63B
2.93B
2.62B
Operating expense
3.53B
3.41B
3.75B
3.57B
Total operating expenses
4.93B
4.97B
5.26B
5.27B
Operating income
1.25B
2.80B
2.56B
1.91B
Other non operating income
-
1.00M
-25.00M
1.00M
EBT including unusual items
794.00M
-4.03B
2.17B
1.68B
EBT excluding unusual items
1.03B
2.64B
2.32B
1.72B
Income tax expense
160.00M
-1.13B
310.00M
363.00M
Effective tax rate
20.15%
28.12%
14.27%
21.59%
Other operating expenses
16.00M
26.00M
-57.00M
1.00M
Net income
636.00M
-2.89B
1.86B
1.32B
Net profit margin
10.30%
-37.22%
23.81%
18.35%
Earnings per share
2.36
6.05
5.65
4.07
Interest and investment income
-
-
22.00M
-
Interest expense
-216.00M
-168.00M
-156.00M
-173.00M
Net interest expenses
-216.00M
-168.00M
-134.00M
-173.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
2.14B
3.71B
3.13B
2.69B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer